news & meetings - latest announcements & happenings | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
https://media-www.fapvoice.com/wp-content/uploads/2017/11/hcistudyiden-1.jpg
clinical trials

Study identifies enhanced impact of treatment for hereditary cancer patients

People with an inherited syndrome called familial adenomatous polyposis (FAP) have a 100% lifetime risk of developing colorectal cancer if they do not seek appropriate medical care. Recent findings published by researchers at Huntsman Cancer Institute at the University of Utah identified a promising prevention treatment for patients with FAP. A new study takes these findings a step further by reporting that the treatment led to a near-complete blockade of cancer growth pathways in polyps isolated from FAP patients. Further, these patients showed evidence of activated immune responses aimed at destroying pre-cancerous polyps. The findings were published today in the journal Cancer Prevention Research.
Nov 6, 2017
https://media-www.fapvoice.com/wp-content/uploads/2017/07/canprev.gif
clinical trials

Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer

Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer. The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
Jul 17, 2017

Youth Rally

Jul 16, 2018

Rare Disease Day at NIH 2018

Mar 1, 2018

Rare Disease Day – Home

Feb 28, 2018

Hereditary Colon Cancer Family Days

Oct 22, 2016

CGA Annual Meeting

Oct 2, 2016
view all (13)